Context Therapeutics Advances CT-95 and CT-202 Programs with Promising Updates at Cancer Conference

Context Therapeutics (CNTX) presents updates on CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's 40th Annual Meeting. The company operates in the biotechnology sector, focusing on innovative treatments for solid tumors. Despite financial challenges, Context Therapeutics shows strong financial health with a high current ratio and no debt. The CT-95 program is a Mesothelin x CD3 bispecific T-cell engager, and CT-202 is a Nectin-4 x CD3 bispecific TCE, with promising preclinical findings and plans to move into clinical testing in 2026.